Would be dificult to estimate BARDA's support this half of the FY19.
The feasability study finalised the last patient back in 08/18, soI cant see much more funds for this.Tthe pivotal trial is not planned to begin until July/August 19 if BARDA goes ahead with it. There is the toxicology study that BARDA is funding currently.
It will be interesting how much BARDA has given PNV H1FY19. Previous was $3.8 FY
Polynovo’s Novosorb is a med-tech Swiss Army Knife, page-17
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.42 |
Change
-0.050(2.02%) |
Mkt cap ! $1.670B | |||
| Open | High | Low | Value | Volume |
| $2.40 | $2.45 | $2.35 | $3.794M | 1.575M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2112 | $2.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.42 | 27096 | 4 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |